Angela Choi
A5051909350- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Animal Virus Infections Studies
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Neonatal Respiratory Health Research
- Asthma and respiratory diseases
- Long-Term Effects of COVID-19
- Respiratory Support and Mechanisms
- RNA Interference and Gene Delivery
- Virology and Viral Diseases
- Animal Disease Management and Epidemiology
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- PARP inhibition in cancer therapy
- T-cell and B-cell Immunology
- interferon and immune responses
- Bacillus and Francisella bacterial research
- Frailty in Older Adults
Moderna Therapeutics (United States)
2021-2025
Icahn School of Medicine at Mount Sinai
2016-2024
University of Maryland, Baltimore
2022
Ghent University Hospital
2022
The University of Queensland
2020
University of Mississippi Medical Center
2020
State Street (United States)
2020
American College of Allergy, Asthma and Immunology
2020
Medical University of South Carolina
2014
McGill University
1994
ABSTRACT Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine demonstrated ~94% efficacy in Phase 3 study and been approved under Emergency Use Authorization. emergence SARS-CoV-2 variants with mutations spike protein, most recently circulating isolates from United Kingdom (B.1.1.7) Republic South Africa (B.1.351), lower neutralization convalescent serum...
The emergence of SARS-CoV-2 variants concern (VOCs) and interest (VOIs) with decreased susceptibility to neutralization has generated in assessments booster doses variant-specific vaccines. Clinical trial participants who received a two-dose primary series the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study ( NCT04405076 ) evaluate objectives safety immunogenicity single dose or variant-modified mRNAs, including multivalent mRNA-1273.211. As is...
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no or doses ranging from 0.3 to 100 μg the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced bronchoalveolar lavages nasal swabs after SARS-CoV-2 challenge vaccinated animals most strongly...
Abstract The current COVID-19 (coronavirus disease 19) pandemic, caused by SARS-CoV-2, disproportionally affects the elderly and people with comorbidities like obesity associated type 2 diabetes mellitus. Small animal models are crucial for successful development validation of antiviral vaccines, therapies to study role that have on outcome viral infections. initially available SARS-CoV-2 isolates require adaptation in order use mouse angiotensin converting enzyme (mACE-2) entry receptor...
In light of multiple variants SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess ability currently available vaccines confer protection against newly emerging variants. Data presented herein indicate immunization with mRNA-1273 vaccine produces neutralizing antibodies key tested, including concern and interest.
Influenza remains a major global health burden. Seasonal vaccines offer protection but can be rendered less effective when the virus undergoes extensive antigenic drift. Antibodies that target highly conserved hemagglutinin stalk protect against drifted viruses, and vaccine constructs designed to induce such antibodies form basis for universal influenza approach. In this study, we analyzed baseline postvaccination serum samples of children (6 59 months), adults (18 49 years), elderly...
Influenza viruses evade human adaptive immune responses due to continuing antigenic changes. This makes it necessary re-formulate and re-administer current seasonal influenza vaccines on an annual basis. Our pan-influenza vaccination approach attempts redirect antibody from the variable, immuno-dominant hemagglutinin head towards conserved-but immuno-subdominant-hemagglutinin stalk. The strategy utilizes sequential immunization with chimeric hemagglutinin-based expressing exotic domains, a...
A look at variant-specific boosters The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants concern (VOCs) has raised the question whether current COVID-19 vaccines protect against VOCs and if a variant specific vaccine may be needed. Of currently identified VOCs, Delta is believed to most transmissible, whereas Beta appears resistant. Corbett et al . looked effect boosting using either original WA-1 strain or variant–specific booster. Around 6 months after...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic disease 2019 (COVID-19) that has led to more than 3 million deaths worldwide. Safe and effective vaccines are now available, including mRNA-1273 prototype vaccine, which encodes for Wuhan SARS-CoV-2 spike (S) protein stabilized in prefusion conformation by proline substitutions. This vaccine showed 94% efficacy prevention symptomatic COVID-19 phase clinical study. Recently,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention symptomatic disease. However, emergence SARS-CoV-2 variants led to concerns viral escape from vaccine-induced immunity. Several have decreased susceptibility neutralization by immunity, most notably B.1.351 (Beta), although overall impact on vaccine remains be...
Abstract The search for vaccines that protect from severe morbidity and mortality because of infection with acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus causes disease 2019 (COVID‐19) is a race against clock virus. Here we describe an amphiphilic imidazoquinoline (IMDQ‐PEG‐CHOL) TLR7/8 adjuvant, consisting conjugated to chain end cholesterol‐poly(ethylene glycol) macromolecular amphiphile. It water‐soluble exhibits massive translocation lymph nodes upon local...
Abstract Background Seasonal influenza remains a global public health concern. A messenger RNA (mRNA)–based quadrivalent seasonal vaccine, mRNA-1010, was investigated in first-in-human, phase 1/2 clinical trial conducted 3 parts. Methods In parts 1 to of this stratified observer-blind study, adults aged ≥18 years were randomly assigned receive single dose (6.25–200 µg) mRNA-1010 or placebo (part 1) an active comparator (Afluria; 2 and 3). Primary study objectives assessment safety,...
Seasonal influenza virus vaccines are generally effective at preventing disease, but need to be well matched circulating strains for maximum benefit. Influenza viruses constantly undergo antigenic changes because of their high mutation rate in the immunodominant haemagglutinin (HA) head domain, which necessitates annual re-formulation and re-vaccination continuing protection. In case pandemic outbreaks, new produced quickly distributed. Novel that redirect immune response towards more...
ABSTRACT The immunogenicity of current influenza virus vaccines is assessed by measuring an increase virus-specific antibodies in a hemagglutination inhibition assay. This method exclusively measures against the hemagglutinin head domain. While this domain immunodominant, it has been shown that titers do not always accurately predict protection from disease. In addition, several novel are currently under development target domain, but rather more conserved sites, including stalk....
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention symptomatic disease. However, emergence SARS-CoV-2 variants led to concerns viral escape from vaccine-induced immunity. Several have decreased susceptibility neutralization by immunity, most notably B.1.351 (Beta), although overall impact on vaccine remains be...
Abstract Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model SARS-CoV-2 infection replicates key features human and may to define immune following vaccination. Here, NHP received either no or doses ranging from 0.3 – 100 μg mRNA-1273, a mRNA encoding the prefusion-stabilized spike (S-2P) protein encapsulated in lipid nanoparticle. mRNA-1273 vaccination elicited robust circulating mucosal antibody responses dose-dependent...
Abstract Due to differences in human and murine angiotensin converting enzyme 2 (ACE-2) receptor, initially available SARS-CoV-2 isolates could not infect mice. Here we show that serial passaging of USA-WA1/2020 strain mouse lungs results “mouse-adapted” (MA-SARS-CoV-2) with mutations S, M, N genes, a twelve-nucleotide insertion the S gene. MA-SARS-CoV-2 infection causes mild disease, more pronounced morbidity depending on genetic background aged obese Two gene associated adaptation (N501Y,...
With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed evaluated domain-based mRNA encoding wild-type spike protein receptor binding domain (RBD) or N-terminal (NTD) alone in combination. An NTD-RBD-linked candidate vaccine, mRNA-1283, showed improved antigen expression, antibody responses, stability at refrigerated temperatures (2° to 8°C) compared with clinically...
Abstract The high variation of the influenza virus hemagglutinin (HA), particularly its immunodominant head epitopes, makes it necessary to reformulate seasonal vaccines every year. Novel that redirect immune response toward conserved epitopes HA stalk domain should afford broad and durable protection. Sequential immunization with chimeric HAs (cHAs) express same distinct exotic heads has been shown elicit levels broadly cross-reactive Abs. In current mouse studies, we tested this strategy...